Tips for Selecting Packaging for Pharmaceutical Drug Manufacturers - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tips for Selecting Packaging for Pharmaceutical Drug Manufacturers
The author describes key considerations for drug manufacturers when evaluating packaging partners.

Pharmaceutical Technology
Volume 35, Issue 3

Differentiate with a unique delivery or administration system

Packaging can be a significant factor in the success of a drug product getting through the regulatory approval process smoothly and to the market quickly. How the product is going to be delivered should be determined based on the clinical application, but research and development is not the time to try a new or high-risk packaging material or system.

Pharmaceutical manufacturers should initially seek out reliable, low-risk packaging materials that are standardized and then apply a unique delivery system to differentiate and optimize delivery. Ideally, the same package should be used for containment from drug research through to commercialization phases.

In many cases, the goal is to move from a vial/stopper system to a prefillable syringe system or auto-injector. Selecting a material that can be used consistently throughout the drug development process, such as a cyclic olefin polymer, can help mitigate risk and reduce time to market. Since this material is plastic, it can be molded into a variety of shapes and sizes, enabling manufacturers to offer unique delivery or administration systems without the need to retest the material for interactions with the drug product.

Having the same material involved in bulk storage, vials, and delivery or administration systems provides consistency in the drug-material interface and minimizes contamination risk as the drug moves from research to clinical trials to commercialization.

Maintain focus on core business

Partnering with a component manufacturer can help drug companies maintain focus on their core business by eliminating the extra time, money, and staff associated with component preparation and sterilization.

For pharmaceutical manufacturers, eliminating the in-house component preparation process can be a cost-effective method of complying with new regulations and streamlining the fill process. By creating a lasting partnership with a packaging manufacturer, drug makers not only help to establish compliance and improve quality, but also have the ability to rely on expert advice and counsel throughout a drug's life cycle.

Containers and administration devices are integral to the safety and efficacy of drug therapies; consequently, the alignment of packaging manufacturers with drug development and production processes will enhance quality, and ultimately, patient safety.

Fran L. DeGrazio is vice-president of marketing and strategic business development at West Pharmaceutical Services, 101 Gordon Dr., Lionville, PA 19341, tel. 610.594.2900, fax 610.594.3000,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here